{"transactions":[{"id":3397215,"issuer":{"id":9673,"kind":"organization","name":"VACCINEX, INC."},"owners":[{"id":9673,"kind":"organization","name":"VACCINEX, INC.","position":1,"cik":"0001205922","reported_name":"VACCINEX, INC.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-10-04T11:36:04.000Z","date":"2019-09-30","kind":"grant","acquired":true,"shares":1856,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Issuer's Director Compensation Program, in a transaction exempt under Rule 16b-3, the reporting person elected to receive these options in lieu of $8,750 for retainer and meeting fees during the third quarter of 2019. The number of options was calculated in accordance with the Black-Scholes valuation model and all of such options are immediately exercisable."}],"balance_after":1856,"derivative":{"exercise_price":7.17,"exercise_date":"2019-09-30","expiration_date":"2019-09-27","underlying":"Common Stock","underlying_shares":1856},"source":{"system":"sec-edgar","filing":"0001209191-19-052508","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1205922/000120919119052508/doc4a.xml","form_type":"4/A","original_submission_date":"2019-10-02"}},{"id":3397214,"issuer":{"id":9673,"kind":"organization","name":"VACCINEX, INC."},"owners":[{"id":9673,"kind":"organization","name":"VACCINEX, INC.","position":1,"cik":"0001205922","reported_name":"VACCINEX, INC.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-10-04T11:22:35.000Z","date":"2019-09-30","kind":"grant","acquired":true,"shares":1856,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the Issuer's Director Compensation Program, in a transaction exempt under Rule 16b-3, the reporting person elected to receive these options in lieu of $8,750 for retainer and meeting fees during the third quarter of 2019. The number of options was calculated in accordance with the Black-Scholes valuation model and all of such options are immediately exercisable."}],"balance_after":1856,"derivative":{"exercise_price":7.17,"exercise_date":"2019-09-30","expiration_date":"2019-09-27","underlying":"Common Stock","underlying_shares":1856},"source":{"system":"sec-edgar","filing":"0001209191-19-052507","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1205922/000120919119052507/doc4a.xml","form_type":"4/A","original_submission_date":"2019-10-02"}},{"id":3400588,"issuer":{"id":9673,"kind":"organization","name":"VACCINEX, INC."},"owners":[{"id":9673,"kind":"organization","name":"VACCINEX, INC.","position":1,"cik":"0001205922","reported_name":"VACCINEX, INC.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-10-02T08:40:01.000Z","date":"2019-09-30","kind":"grant","acquired":true,"shares":1856,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the Issuer's Director Compensation Program, in a transaction exempt under Rule 16b-3, the reporting person elected to receive these options in lieu of $8,750 for retainer and meeting fees during the third quarter of 2019. The number of options was calculated in accordance with the Black-Scholes valuation model and all of such options are immediately exercisable."}],"balance_after":1856,"derivative":{"exercise_price":7.17,"exercise_date":"2019-09-30","expiration_date":"2019-09-27","underlying":"Common Stock","underlying_shares":1856},"source":{"system":"sec-edgar","filing":"0001209191-19-051418","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1205922/000120919119051418/doc4.xml","form_type":"4"}},{"id":3400587,"issuer":{"id":9673,"kind":"organization","name":"VACCINEX, INC."},"owners":[{"id":9673,"kind":"organization","name":"VACCINEX, INC.","position":1,"cik":"0001205922","reported_name":"VACCINEX, INC.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-10-02T07:59:15.000Z","date":"2019-09-30","kind":"grant","acquired":true,"shares":1856,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Issuer's Director Compensation Program, in a transaction exempt under Rule 16b-3, the reporting person elected to receive these options in lieu of $8,750 for retainer and meeting fees during the third quarter of 2019. The number of options was calculated in accordance with the Black-Scholes valuation model and all of such options are immediately exercisable."}],"balance_after":1856,"derivative":{"exercise_price":7.17,"exercise_date":"2019-09-30","expiration_date":"2019-09-27","underlying":"Common Stock","underlying_shares":1856},"source":{"system":"sec-edgar","filing":"0001209191-19-051415","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1205922/000120919119051415/doc4.xml","form_type":"4"}}]}